Literature DB >> 10088640

Molecular basis for polycythemia.

J F Prchal1, J T Prchal.   

Abstract

This overview concentrates on familial and congenital polycythemias in the context of other polycythemic disorders, with emphasis on those with established molecular lesions. Recent advances in the regulation of erythropoiesis, as they may relate to polycythemic states, are discussed as a background for those well-defined polycythemic states wherein the molecular defect has not yet been elucidated. Primary familial congenital polycythemias and congenital and familial secondary polycythemias, including hemoglobin mutants, methemoglobinemias and congenital 2,3-bisphosphoglycerate deficiency, are discussed. The most common primary polycythemia, polycythemia vera, as well as the only likely endemic congenital secondary polycythemia, known as Chuvash polycythemia, are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088640     DOI: 10.1097/00062752-199903000-00008

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  9 in total

Review 1.  Adult pulmonary Langerhans' cell histiocytosis.

Authors:  A Tazi; P Soler; A J Hance
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

2.  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

Authors:  Xiaoli Wang; Sonam Prakash; Min Lu; Joseph Tripodi; Fei Ye; Vesna Najfeld; Yan Li; Myron Schwartz; Rona Weinberg; Paul Roda; Attilio Orazi; Ronald Hoffman
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

3.  Identification of an acquired JAK2 mutation in polycythemia vera.

Authors:  Runxiang Zhao; Shu Xing; Zhe Li; Xueqi Fu; Qingshan Li; Sanford B Krantz; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2005-04-29       Impact factor: 5.157

4.  Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.

Authors:  Xiaoli Wang; Wei Zhang; Joseph Tripodi; Min Lu; Mingjiang Xu; Vesna Najfeld; Yan Li; Ronald Hoffman
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

Review 5.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

6.  Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells.

Authors:  Zhaohui Ye; Cyndi F Liu; Lucie Lanikova; Sarah N Dowey; Chaoxia He; Xiaosong Huang; Robert A Brodsky; Jerry L Spivak; Josef T Prchal; Linzhao Cheng
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

7.  Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.

Authors:  Roberto H Nussenzveig; Jorge Cortes; Matjaz Sever; Alfonso Quintás-Cardama; Pat Ault; Taghi Manshouri; Carlos Bueso-Ramos; Josef T Prchal; Hagop Kantarjian; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2009-05-30       Impact factor: 2.490

8.  JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.

Authors:  Xiaoli Wang; Fei Ye; Joseph Tripodi; Cing Siang Hu; Jiajing Qiu; Vesna Najfeld; Jesse Novak; Yan Li; Raajit Rampal; Ronald Hoffman
Journal:  Blood       Date:  2014-09-05       Impact factor: 22.113

9.  Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.

Authors:  Amos Gaikwad; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.